Intuitive Surgical’s Growth Engine Stutters as a New Rival Enters the Operating Room
Published on 07/23/2026 at 18:22 | Redaktion boerse-global.de
The da Vinci surgical robot remains the undisputed heavyweight of robotic surgery, but Intuitive Surgical’s stock is trading as though the crown is slipping. Shares touched a fresh 52-week low of €298.05 on July 23, recovering only marginally to €299.35 — a far cry from the January peak of €516.50. The year-to-date decline now stands at roughly 39%, a brutal repricing driven not by disappointing earnings, but by two converging threats: a deceleration in U.S. procedure growth and the arrival of a formidable new competitor.
Strong Earnings, But the Market Sees a Different Story
On the surface, Intuitive Surgical’s second-quarter results were anything but weak. Adjusted earnings per share of $2.80 crushed the consensus estimate of $2.48, while revenue climbed 18.4% year-over-year to $2.89 billion. Profitability also improved: adjusted gross margin edged up 30 basis points to 70%, and adjusted operating margin jumped 330 basis points to 42%. The company raised its full-year gross margin guidance to 68–69%.
Yet investors focused on what lay beneath the headline numbers. Growth in da Vinci procedures across the U.S. slowed to roughly 12% in the quarter, below the trajectory that has historically justified the stock’s premium valuation. The company’s full-year global procedure growth forecast of 13.5% to 15.5% now looks less assured. At roughly 9.9 times forward revenue — the lowest multiple in 18 months and well below the median of 15.9 — the market is signaling that the old growth assumptions no longer hold.
A separate factor compounded the unease: a Class II recall of certain da Vinci components and reports of declining surgical volumes at large hospital operators. These operational hiccups, combined with insider stock sales totaling $3.1 million over the past three months, have eroded confidence further. Executives including SVP Iman Jeddi and EVP Gary Loeb trimmed their positions in June at prices above current levels.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Johnson & Johnson Wins FDA Approval for Ottava
The competitive landscape shifted decisively on July 22, when the U.S. Food and Drug Administration granted marketing authorization to Johnson & Johnson for its Ottava surgical robot. Ottava is the first table-integrated robotic system approved in the U.S. for soft-tissue surgery, a design that reduces operating room footprint by an estimated 30% to 50%. Initial approved procedures include gastric bypass, gastrectomy, cholecystectomy, sleeve gastrectomy, appendectomy, and hiatal hernia repair.
Johnson & Johnson plans a phased commercial rollout, with later expansion into Japan and Western Europe. That puts Ottava in direct competition with da Vinci and Medtronic’s Hugo system. While only about 8% of surgeries worldwide are currently robot-assisted — leaving ample room for multiple players — the arrival of a well-capitalized rival with deep hospital relationships changes the calculus. A J.P. Morgan analyst noted that Johnson & Johnson will likely pursue additional clearances for urological procedures, a segment where Intuitive Surgical remains dominant.
Analyst Reactions: Cautious, Divided, and Downward
The analyst community responded with a flurry of target cuts, though opinions vary widely. Bernstein slashed its price target from $750 to $685, Stifel from $670 to $550, Citigroup to $500, and TD Cowen to $520. Goldman Sachs held firm at $558, while Deutsche Bank stands out with a sell rating and a $366 target. Simply Wall St lowered its fair value estimate from $565.25 to $501.73, citing a reduced revenue growth assumption of 12.14% versus 13.09% previously.
Institutional positioning tells a similarly mixed story. Dimensional Fund Advisors increased its stake by 3.6% in the first quarter to 645,181 shares, while CI Investments slashed its position by 33.1%, selling 61,937 shares over the same period.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
The Core Question: Temporary Blip or Structural Shift?
Intuitive Surgical still holds a commanding lead in robotic surgery, with $8.63 billion in cash and a business that generated a 40.9% adjusted operating margin in the quarter. The company’s digital offerings, including the Ion platform, continue to expand. CEO Dave Rosa expressed satisfaction with progress across the portfolio.
But the stock’s slide reflects a market wrestling with a fundamental uncertainty: Is the slowdown in U.S. procedure growth a temporary soft patch, or does it mark the beginning of a structural shift as Johnson & Johnson enters the field? With the shares trading near their lowest valuation in 18 months and a fresh competitor now FDA-approved, the burden of proof has shifted. Intuitive Surgical must now demonstrate that its growth story can withstand both a maturing U.S. market and a rival that is determined to claim its share of the operating room.
Ad
Intuitive Surgical Stock: New Analysis - 23 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
